Item 1. |
Security and Issuer |
This Schedule 13D (this Statement) relates to the common stock, par value $0.001 per share (the Common Stock), of
Perspective Therapeutics, Inc., a Delaware corporation (the Issuer). The Issuers principal executive offices are located at 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121.
Item 2. |
Identity and Background |
(a)-(c) and (f):
The names of the persons filing this Statement
are Lantheus Holdings, Inc., a Delaware corporation (Lantheus Holdings), and Lantheus Alpha Therapy, LLC, a Delaware limited liability company (Lantheus Alpha, and together with Lantheus Holdings, the
Reporting Persons). The principal business of Lantheus Holdings is the development, manufacturing, and commercialization of innovative diagnostic medical imaging diagnostics (across a range of imaging modalities, including
echocardiography and nuclear imaging), radiotherapeutics and artificial intelligence solutions. The principal business of Lantheus Alpha is to enter into the transactions contemplated by the Investment Agreement.
The address of the principal business and the principal office of each of the Reporting Persons is 201 Burlington Road, South Building, Bedford, MA 01730.
The name, business address, present principal occupation or employment and citizenship of each director and executive officer of the Reporting Persons
are set forth on Schedule A to this Statement, and are incorporated herein by reference.
The Reporting Persons have entered into a Joint Filing
Agreement, a copy of which is filed with this Statement as Exhibit 99.7, pursuant to which the Reporting Persons have agreed to file this Statement jointly in accordance with the provisions of
Rule 13d-1(k) of the Act.
(d) and (e):
During the last five years, none of the Reporting Persons nor, to the knowledge of each of the Reporting Persons, any of the persons named on Schedule A
attached hereto, has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of
such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3. |
Source and Amount of Funds or Other Consideration |
Item 6 of this Statement is incorporated herein by reference. Capitalized terms used but not defined in this Item 3 or the preceding Items of this Statement
are defined in Item 6.
On January 22, 2024, Lantheus Alpha purchased 56,342,355 shares of the Issuers Common Stock at a purchase price per
share of $0.37 in a private placement transaction (the Purchase). The total consideration for the Purchase was approximately $20.8 million in cash.
On January 8, 2024, the Issuer and Lantheus Alpha entered into an Option Agreement attached hereto as Exhibit 99.3. Pursuant to the Option Agreement, as
partial consideration for the rights afforded to Lantheus Alpha thereunder, Lantheus Alpha agreed to pay a one-time payment of $28.0 million, subject to certain withholding provisions related to the
closing contemplated by the APA (as defined below). As further consideration for the rights granted to Lantheus Alpha under the Option Agreement, the Issuer and Lantheus Alpha also entered into the Investment Agreement.
The source of funds for the transactions described in this Item 3 was general working capital and cash on hand of the Reporting Persons.